62 related articles for article (PubMed ID: 26355285)
1. Correction to Exploring the Effect of Conjugation Site and Chemistry on the Immunogenicity of an anti-Group B Streptococcus Glycoconjugate Vaccine Based on GBS67 Pilus Protein and Type V Polysaccharide.
Nilo A; Passalacqua I; Fabbrini M; Allan M; Usera A; Carboni F; Brogioni B; Pezzicoli A; Cobb J; Romano MR; Margarit I; Hu QY; Berti F; Adamo R
Bioconjug Chem; 2015 Oct; 26(10):2167. PubMed ID: 26355285
[No Abstract] [Full Text] [Related]
2. Exploring the Effect of Conjugation Site and Chemistry on the Immunogenicity of an anti-Group B Streptococcus Glycoconjugate Vaccine Based on GBS67 Pilus Protein and Type V Polysaccharide.
Nilo A; Passalacqua I; Fabbrini M; Allan M; Usera A; Carboni F; Brogioni B; Pezzicoli A; Cobb J; Romano MR; Margarit I; Hu QY; Berti F; Adamo R
Bioconjug Chem; 2015 Aug; 26(8):1839-49. PubMed ID: 26230938
[TBL] [Abstract][Full Text] [Related]
3. Anti-Group B Streptococcus Glycan-Conjugate Vaccines Using Pilus Protein GBS80 As Carrier and Antigen: Comparing Lysine and Tyrosine-directed Conjugation.
Nilo A; Morelli L; Passalacqua I; Brogioni B; Allan M; Carboni F; Pezzicoli A; Zerbini F; Maione D; Fabbrini M; Romano MR; Hu QY; Margarit I; Berti F; Adamo R
ACS Chem Biol; 2015 Jul; 10(7):1737-46. PubMed ID: 25906283
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and immunological activity of an oligosaccharide-conjugate as a vaccine candidate against Group A Streptococcus.
Auzanneau FI; Borrelli S; Pinto BM
Bioorg Med Chem Lett; 2013 Nov; 23(22):6038-42. PubMed ID: 24103300
[TBL] [Abstract][Full Text] [Related]
5. Glycoconjugate vaccines.
Pace D
Expert Opin Biol Ther; 2013 Jan; 13(1):11-33. PubMed ID: 22992106
[TBL] [Abstract][Full Text] [Related]
6. Designer vaccines to prevent infections due to group B Streptococcus.
Kasper DL
Proc Assoc Am Physicians; 1995 Oct; 107(3):369-73. PubMed ID: 8608425
[TBL] [Abstract][Full Text] [Related]
7. Use of animal testing for evaluating glycoconjugate vaccine immunogenicity.
Madore DV; Strong N; Eby R
Dev Biol Stand; 1999; 101():49-56. PubMed ID: 10566775
[TBL] [Abstract][Full Text] [Related]
8. Improved conjugation and purification strategies for the preparation of protein-polysaccharide conjugates.
Suárez N; Massaldi H; Franco Fraguas L; Ferreira F
J Chromatogr A; 2008 Dec; 1213(2):169-75. PubMed ID: 18992885
[TBL] [Abstract][Full Text] [Related]
9. Conjugation of β-glucan markedly increase the immunogencity of meningococcal group Y polysaccharide conjugate vaccine.
Qiao W; Ji S; Zhao Y; Hu T
Vaccine; 2015 Apr; 33(17):2066-72. PubMed ID: 25728319
[TBL] [Abstract][Full Text] [Related]
10. Glycoconjugate vaccines: future combinations.
Paradiso PR; Lindberg AA
Dev Biol Stand; 1996; 87():269-75. PubMed ID: 8854027
[TBL] [Abstract][Full Text] [Related]
11. Immunization with the RrgB321 fusion protein protects mice against both high and low pilus-expressing Streptococcus pneumoniae populations.
Moschioni M; De Angelis G; Harfouche C; Bizzarri E; Filippini S; Mori E; Mancuso G; Doro F; Barocchi MA; Ruggiero P; Masignani V
Vaccine; 2012 Feb; 30(7):1349-56. PubMed ID: 22210141
[TBL] [Abstract][Full Text] [Related]
12. Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm.
Margarit I; Rinaudo CD; Galeotti CL; Maione D; Ghezzo C; Buttazzoni E; Rosini R; Runci Y; Mora M; Buccato S; Pagani M; Tresoldi E; Berardi A; Creti R; Baker CJ; Telford JL; Grandi G
J Infect Dis; 2009 Jan; 199(1):108-15. PubMed ID: 19086816
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of PRP-T combined with DTP: excretion of capsular polysaccharide and antibody response in the immediate post-vaccination period.
Miller MA; Meschievitz CK; Ballanco GA; Daum RS
Pediatrics; 1995 Apr; 95(4):522-7. PubMed ID: 7700752
[TBL] [Abstract][Full Text] [Related]
14. Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus.
Baker CJ; Rench MA; Edwards MS; Carpenter RJ; Hays BM; Kasper DL
N Engl J Med; 1988 Nov; 319(18):1180-5. PubMed ID: 3050524
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
Dashefsky B; Wald E; Guerra N; Byers C
Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519
[TBL] [Abstract][Full Text] [Related]
16. Use of Lactococcus lactis expressing pili from group B Streptococcus as a broad-coverage vaccine against streptococcal disease.
Buccato S; Maione D; Rinaudo CD; Volpini G; Taddei AR; Rosini R; Telford JL; Grandi G; Margarit I
J Infect Dis; 2006 Aug; 194(3):331-40. PubMed ID: 16826481
[TBL] [Abstract][Full Text] [Related]
17. Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults.
Baker CJ; Rench MA; Paoletti LC; Edwards MS
Vaccine; 2007 Jan; 25(1):55-63. PubMed ID: 16919857
[TBL] [Abstract][Full Text] [Related]
18. N-propionylation.
Guo Z; Jennings H
Methods Mol Med; 2001; 66():55-60. PubMed ID: 21336747
[TBL] [Abstract][Full Text] [Related]
19. The design of semi-synthetic and synthetic glycoconjugate vaccines.
Costantino P; Rappuoli R; Berti F
Expert Opin Drug Discov; 2011 Oct; 6(10):1045-66. PubMed ID: 22646863
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and reactogenicity of 23-valent pneumococcal polysaccharide vaccine among pregnant Filipino women and placental transfer of antibodies.
Quiambao BP; Nohynek HM; Käyhty H; Ollgren JP; Gozum LS; Gepanayao CP; Soriano VC; Makela PH
Vaccine; 2007 May; 25(22):4470-7. PubMed ID: 17442467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
